

14 Jan 2024 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: major takeaways and highlights from the JP Morgan meeting; J&J bets on ADCs with Ambrx buy; the Indian GLP-1 battleground; and Scrip asks what 2024 holds for business strategy and leadership.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 January 2024, including: major takeaways and highlights from the J.P. Morgan meeting; [Johnson & Johnson](#) bets on ADCs with [Ambrx Biopharma, Inc.](#) buy; the Indian GLP-1 battleground; and Scrip asks what 2024 holds for business strategy and leadership.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[J.P. Morgan 2024: Optimism With An Undercurrent Of Tension](#)" - Scrip, 10 Jan, 2024.)

(Also see "[J&J Makes Its Biggest Bet Yet On Antibody-Drug Conjugates With Ambrx Buyout](#)" - Scrip, 8 Jan, 2024.)

(Also see "[J.P. Morgan Day Three: Biogen Still Shopping For Deals, Sanofi Explains Its View On Oncology](#)" - Scrip, 10 Jan, 2024.)

(Also see "[Battleground GLP-1s: After Chinese Firms, Glenmark Debuts Liraglutide; More Coming](#)" -

# SCRIP

CITELINE COMMERCIAL

Scrip, 8 Jan, 2024.)

(Also see "[\*Scrip Asks...What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership\*](#)" - Scrip, 9 Jan, 2024.)

[\*Click here to explore this interactive content online\*](#) 